A few days ago, a paper published in the famous journal, The New England Journal of Medicine (NEJM), discussed the potential of a new oral #GLP-1 receptor agonist, #Orforglipron, which is currently in phase 3 trials by Eli Lilly
Like most medications, tirzepatide can cause side effects, though many people tolerate it well, especially when starting at a low dose
Additionally, variability in provider expertise and device availability can impact treatment outcomes and equity of care
A good candidate for Wellness Weight Management in Gig Harbor, WA, is someone struggling with excess weight or obesity due to environmental, behavioral, or genetic factors